Jason A. Keyes - 06 Aug 2026 Form 4 Insider Report for BlossomHill Therapeutics, Inc. (BLSM)

Reporting relationship: Chief Financial Officer
Issuer ticker: BLSM
Reported as of: 06 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Aug 2026, 18:27:21 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Vincent Liptak, Attorney-in-Fact

Key filing fact

Jason A. Keyes filed Form 4 for BlossomHill Therapeutics, Inc. (BLSM) on 10 Aug 2026.

Key facts

This page summarizes Jason A. Keyes's Form 4 filing for BlossomHill Therapeutics, Inc. (BLSM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Aug 2026, 18:27.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001678152 Primary reporting owner

Keyes Jason A

Relationship: Chief Financial Officer
Address: C/O BLOSSOMHILL THERAPEUTICS, INC., 10255 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO
Signature: /s/ Vincent Liptak, Attorney-in-Fact
Signature date: 10 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLSM transaction

Common Stock

Purchase

Transaction value
Shares: +700
Change %
Price: $16.00^*
Shares after: 700
Date: 10 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLSM transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +56,746
Change %
Price: $0.000000^*
Shares after: 56,746
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,746
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.